| Literature DB >> 32775981 |
Hirokazu Marumoto1, Takaya Sasaki1, Nobuo Tsuboi1, Tatsuhiko Ito2, Masahiro Ishikawa1, Makoto Ogura1, Masato Ikeda1, Takashi Yokoo1.
Abstract
RATIONALE &Entities:
Keywords: Anorexia nervosa; chronic kidney disease; eating disorder; extreme weight loss; hypokalemia; hypokalemic nephropathy; kidney biopsy; renal replacement therapy
Year: 2020 PMID: 32775981 PMCID: PMC7406847 DOI: 10.1016/j.xkme.2020.03.007
Source DB: PubMed Journal: Kidney Med ISSN: 2590-0595
Patient Characteristics
| Variables | All Subjects (n = 14) | Variables | All Subjects (n = 14) |
|---|---|---|---|
| Female sex | 14 (100%) | Aldosterone to renin activity ratio | 16.9 [10.3, 38.1] |
| Time to the first visit, y | 17.5 [10.8, 23.5] | Plasma aldosterone concentration, pg/mL | 128 [77, 465] |
| Age at the first visit, y | 39.0 [33.3, 44.0] | Plasma renin activity, ng/mL/h | 11.4 [2.3, 19.8] |
| Age at eating disorder onset, y | 19.5 [17.3, 26.0] | pH | 7.4 [7.4, 7.5] |
| BMI, kg/m2 | 13.4 [12.4, 15.1] | Base excess | 3.2 [−6.3, 13.9] |
| BSA, m2 | 1.21 [1.19, 1.33] | P | 44 [40, 51] |
| Follow-up period, y | 3.1 [0.7, 5.9] | HCO3-, mmol/L | 27.4 [19.2, 39.6] |
| Urinary protein excretion, g/g Cr | 0.14 [0.04, 0.44] | ||
| Serum creatinine, mg/dL | 1.9 [1.2, 3.5] | Urinary β2-MG, μg/g Cr | 4,000 [540, 54,986] |
| eGFR, mL/min/1.73 m2 | 20.9 [8.5, 32.2] | Urinary NAG, U/g Cr | 18.3 [8.9, 39.0] |
| Serum urea nitrogen, mg/dL | 29.7 [17.0, 55.6] | FENa, % | 0.28 [0.08, 1.38] |
| Serum sodium, mmol/L | 138 [136, 141] | ||
| Serum potassium, mmol/L | 2.7 [2.2, 3.1] | Use of diuretics or laxatives | 7 (50%) |
| Serum chloride, mmol/L | 95 [87, 100] | Habit of vomiting | 13 (93%) |
| Serum phosphorus, mg/dL | 3.85 [3.20, 5.17] | Hypertension | 0 (0%) |
| Serum calcium, mg/dL | 9.15 [8.62, 9.57] | Use of RAAS inhibitors | 0 (0%) |
| Serum magnesium, g/dL | 2.30 [2.02, 2.70] | Death | 2 (14%) |
Note: Values for categorical variables are given as number (percent); values for continuous variables are given as median [interquartile range]. Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; serum urea nitrogen in mg/dL to mmol/L, ×0.357; serum calcium in mg/dL to mmol/L, ×0.2495.
Abbreviations: BMI, body mass index; BSA, body surface area; Cr, creatinine; eGFR, estimated glomerular filtration rate; FENa, fractional excretion of sodium; MG, macroglobulin; NAG, N-acetyl-β-d-glucosaminidase; RAAS, renin-angiotensin-aldosterone system.
Comparison Between 2 Groups With or Without Kidney Outcomes and Kidney Biopsy During Follow-up
| Variables | Kidney Outcomes | |
|---|---|---|
| Without Kidney Outcomes | With Kidney Outcomes | |
| (n = 5) | (n = 9) | |
| At diagnosis | ||
| Years to first visit to nephrologist (years) | 14 [6, 18] | 19 [13, 24] |
| Age at first visit to a nephrologist, y | 34 [33, 35] | 42 [37, 48] |
| Age at eating disorder onset, y | 20 [17, 27] | 19 [18, 23] |
| Body weight, kg | 39 [35, 40] | 31 [27, 33] |
| BMI, kg/m2 | 15.2 [14.6, 15.6] | 12.8 [11.0, 13.9] |
| BSA, m2 | 1.34 [1.26, 1.38] | 1.19 [1.12, 1.22] |
| Serum albumin, g/dL | 3.9 [3.2, 4.6] | 3.5 [3.4, 4.0] |
| eGFR, mL/min/1.73 m2 | 34.7 [27.0, 57.5] | 13.8 [10.7, 40.4] |
| Serum urea nitrogen, mg/dL | 24 [11, 32] | 46 [20, 63] |
| Serum sodium, mmol/L | 136 [135, 138] | 139 [137, 141] |
| Serum potassium, mmol/L | 2.6 [2.4, 2.8] | 2.8 [2.1, 3.1] |
| Serum chloride, mmol/L | 95 [95, 99] | 91 [85, 100] |
| Serum calcium, mg/dL | 9.2 [8.6, 9.5] | 9.1 [8.7, 9.6] |
| Serum magnesium, g/dL | 1.95 [1.85, 2.02] | 2.60 [2.32, 4.38] |
| pH | 7.44 [7.43, 7.45] | 7.44 [7.25, 7.47] |
| Base excess, mmol/L | 2.25 [-2.75, 8.90] | 3.20 [-12.05, 14.03] |
| PCO2, mm Hg | 43.6 [39.7, 50.9] | 43.7 [41.4, 51.5] |
| HCO3-, mmol/L | 26.7 [20.8, 34.8] | 27.4 [14.6, 39.6] |
| ACTH, pg/mL | 17.9 [15.8, 20.1] | 26.8 [20.9, 28.8] |
| Cortisol, μg/dL | 15.0 [11.3, 19.7] | 16.5 [13.0, 17.7] |
| Aldosterone to renin activity ratio | 24.1 [16.2, 34.9] | 14.7 [10.3, 34.5] |
| Plasma aldosterone concentration, pg/mL | 128 [93, 252] | 130 [77, 779] |
| Plasma renin activity, ng/mL/h | 9.9 [2.6, 18] | 13 [2.7, 37] |
| During follow-up | ||
| Follow-up, y | 1.8 [0.3, 3.3] | 4.8 [2.0, 6.0] |
| Serum creatinine at last observation, mg/dL | 1.04 [0.93, 1.71] | 3.65 [3.04, 4.84] |
| eGFR at last observation, mL/min/1.73 m2 | 51.6 [27.9, 58.8] | 12.9 [9.57, 16.2] |
| Patient reached doubling of creatinine | 0 | 6 |
| Patient reached ESKD | 0 | 7 |
Note: Values for categorical variables are given as number; values for continuous variables are given as median [interquartile range]. Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; serum urea nitrogen in mg/dL to mmol/L, ×0.357; serum calcium in mg/dL to mmol/L, ×0.2495.
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.
Clinical and Histopathologic Findings at Biopsy
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age at biopsy, y | 30s | 30s | 30s | 20s |
| Reasons for renal biopsy indication | Elevated tubulointerstitial marker, hypokalemia | Unknown renal dysfunction | Unknown renal dysfunction | Rapidly progressing renal dysfunction, hypokalemia |
| Duration from development of an eating disorder to biopsy, y | 0 | 9 | 14 | 10 |
| BMI, kg/m2 | 17.6 | 13.9 | 14.6 | 14.9 |
| BSA, m2 | 1.44 | 1.30 | 1.26 | 1.19 |
| Serum creatinine, mg/dL | 0.59 | 3.83 | 2.99 | 1.4 |
| eGFR, mL/min/1.73 m2 | 94 | 13 | 16 | 40 |
| Serum potassium, mmol/L | 2.8 | 2.9 | 3.3 | 2.1 |
| Serum magnesium, g/dL | 2.1 | 2.3 | 1.8 | 5.2 |
| pH | 7.478 | 7.471 | 7.403 | 7.436 |
| HCO3-, mmol/L | 32.4 | 39.4 | 20.6 | 26.9 |
| IF/TA, % | 5 | 50 | 60 | 30 |
| Calcification | NA | NA | NA | + |
| Cortex medulla ratio | 9:1 | 9:1 | 8:2 | 10:0 |
| Glomerular number | 47 | 35 | 37 | 146 |
| GGS, % | 2 | 23 | 43 | 3 |
| Hypertrophy of JGA | + | ± | − | − |
Note: Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4.
Abbreviations: BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; GGS, global glomerular sclerosis; IF/TA, interstitial fibrosis and/or tubular atrophy; JGA, juxtaglomerular apparatus; NA, not available.
Figure 1Kidney histopathologic findings. (A) Case 1: a woman in her 30s with normal kidney function exhibited hyperplasia of the juxtaglomerular apparatus (periodic acid–Schiff staining; original magnification, ×400). (B) Case 1: tubulointerstitium damage was mild (interstitial fibrosis and/or tubular atrophy < 5%). (C) Case 2: a woman in her 30s with severely decreased kidney function; interstitial expansion and inflammation were found (B, C: Masson trichrome staining; original magnification, ×100). (D) Case 2: most infiltrating cells in the tubulointerstitium were mononuclear cells (hematoxylin and eosin staining; original magnification, ×200). (E) Case 3: a woman in her 30s with severely decreased kidney function showed marked tubulointerstitial damage with cast formation and global glomerulosclerosis (periodic acid–Schiff staining; original magnification, ×100). (F) Most glomeruli showed global glomerulosclerosis of the obsolescence type (Masson trichrome staining; original magnification, ×100). (G) Case 4: a woman in her 20s with moderately decreased kidney function. Analyses of kidney biopsy specimens showed that most glomeruli on the surface layer of the renal cortex were collapsed (Masson trichrome staining; original magnification, ×50). (H) Case 4: enlargement of the boxed area in G (Masson trichrome staining; original magnification, ×100).